Board of Directors

David Brunel – Mr. Brunel joined KromaTiD’s Board in 2019 and severs as Chairman. Mr. Brunel was a co-founder and CEO of Biodesix from 2006 to 2020, a company that develops and commercializes non-invasive blood-based molecular diagnostic tests for oncology. Prior to Biodesix, Mr. Brunel was co-founder and President of SomaLogic, a company creating protein capture arrays for sensitive, high-throughput, quantitative diagnostics. He was also founder and CEO of Unidata, Inc. which merged with Vmark Software to create Ardent Software, Inc., where he was CEO. He served as CEO of both Codestream, Ltd, acquired by Blue Phoenix Solutions, and eMotion, Inc., acquired by Corbus, and now part of Getty Images. Additionally, Mr. Brunel serves on the board of Anark Corporation, AmideBio, HepQuant, and InOn Health. David has a BS in Chemistry from Colorado State University, and MA in International Studies from Denver University.

James E. Chomas, Ph.D. – Dr. Chomas joined KromaTiD’s board in 2021, and assumed the role of CEO in 2023.  Jim has served in multiple CEO and leadership roles including CEO of CereHealth, a medical analytics company focused on brain health, and president of Blue Room Investing, a private equity firm.  Jim founded Surefire Medical in 2009 (now TriSalus Life Sciences), an innovative oncology therapeutics and drug delivery company, which he led from initial patents through successful worldwide commercialization.  TriSalus IPO’d in 2023 and continues to thrive in the public market (Nasdaq: TLSI).  Jim served in leadership roles at Cabochon (acquired by Ulthera) and Siemens Healthcare Solutions.  He has authored 57 patents in medical technology and serves as an advisor to multiple healthcare companies in the Colorado bioscience ecosystem as well as a Board Director for Triangle Biosciences.  Jim holds a dual B.S.E in electrical and biomedical engineering from Duke University and a PhD from University of Virginia.

Walt Young – Joined KromaTiD’s Board in 2021. He has over 50 years’ experience in leading organizations and has held senior positions at four public companies: BF Goodrich, The Budd Company, The Henley Group and Champion Enterprises.  As Chair and CEO of Champion Enterprises, Walt was recognized by Fortune as a “Superstar” and by the Harvard Business School as one of the 19 top business leaders of the 1990s.  He has focused on entrepreneurial start-ups since 2003 and has led and assisted over 100 entities to raise more than $130M in capital.    Walt has a B.A. degree in Liberal Arts from Muskingum University, and a M.B.A. degree from Pennsylvania State University.

Terry Opgenorth, Ph.D. – Dr. Opgenorth joined KromaTiD’s Board in 2010.  Most recently, he served as Vice President and Executive Director of LAUNCHPAD at CSU Ventures, CEO of Vidasym, a company developing drugs for chronic kidney disease, and CSO/Co-Founder of VetDC, a veterinary oncology company.  Prior to that Terry spent 20yrs with Abbott Laboratories (now AbbVie), most recently as Vice President of Metabolic Disease Research, Antiviral (HCV) Research and Target-Lead Discovery Research in Global Pharmaceutical R & D. He is a Director for VetDC, Forecast Orthopedics and PhotonPharma. Dr. Opgenorth holds a B.A. in Liberal Arts (biology major) from Calvin University and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.

Priya Gogoi – Ms. Gogoi joined KromaTiD’s board in 2021. She co-founded Celsee, Inc., in 2010, a life-science tools company developing products for cancer research and single-cell sequencing, acquired by BioRad Laboratories in 2020. She works as an investment analyst and startup mentor through Gogo Innovation Consulting LLC, is a contributing author to Entrepreneur Media, and serves on the board for International Child Care.   Priya holds a BS degree from Gauhati University, an Executive MBA from Ross School of Business at the University of Michigan, and M.S. degree in Cell and Molecular Biology from Eastern Michigan University.

Jack Ball – Mr. Ball joined KromaTiD’s board in 2021. He is President of Tyball Associates, a commercialization strategy consulting firm in the biotech tools space. He serves on the board of directors of Carterra, Cytek Biosciences, and NanoCellect. Mr. Ball was on the board at Swift Bioscience for 11 years until it sold to Integrated DNA Technology in March 2021. Most recently he was CEO, Solulink. Prior to that he was CCO at Accuri Cytometers which was sold to Becton Dickinson in March 2011, and before that he was CEO of Amnis Corporation. He also served in executive roles at Molecular Probes, Orchid Biosciences, and Amersham Pharmacia Biotech (where he rose to President for North America).  Mr. Ball has a B.S. degree in Agriculture from University of Georgia.